Disease · MONDO_0005009
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| LCZ696 vs Enalapril: serious adverse events | 1,937 of 4,203 | 2,142 of 4,229 | 8,432 | NCT01035255 | Trial comparisons |
| LCZ696 vs Enalapril: Number of Patients With First Confirmed Renal Dysfunction | 94 of 4,187 | 108 of 4,212 | 8,399 | NCT01035255 | Trial comparisons |
| LCZ696 vs Enalapril: Number of Patients - All-cause Mortality | 711 of 4,187 | 835 of 4,212 | 8,399 | NCT01035255 | Trial comparisons |
Percutaneous Coronary Intervention Group vs Medical Therapy Group: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | 230 of 1,101 | 219 of 1,100 | 2,201 | NCT00004562 | Trial comparisons |
| Percutaneous Coronary Intervention Group vs Medical Therapy Group: serious adverse events | 226 of 1,101 | 227 of 1,100 | 2,201 | NCT00004562 | Trial comparisons |
| Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events | 224 of 395 | 173 of 386 | 781 | NCT00486759 | Trial comparisons |
| Sertraline vs Placebo: serious adverse events | 57 of 234 | 63 of 235 | 469 | NCT00078286 | Trial comparisons |
| White Participants--Atenolol vs Black Participants-Atenolol: deaths from any cause | 0 of 85 | 0 of 69 | 154 | NCT00837902 | Trial comparisons |
| White Participants--Atenolol vs Black Participants-Atenolol: serious adverse events | 0 of 85 | 0 of 69 | 154 | NCT00837902 | Trial comparisons |
| OPC-41061 15mg vs Placebo: serious adverse events | 2 of 53 | 7 of 57 | 110 | NCT00462670 | Trial comparisons |
| Intravenous (IV) Insulin vs Subcutaneous (SQ) Insulin: serious adverse events | 0 of 26 | 0 of 39 | 65 | NCT00812253 | Trial comparisons |
| CHF Peptide vs Non CHF Peptide: serious adverse events | 0 of 25 | 4 of 25 | 50 | NCT01584518 | Trial comparisons |
| CRV-IR vs SK&F-105517-D: serious adverse events | 1 of 22 | 3 of 19 | 41 | NCT00742508 | Trial comparisons |
| Candesartan vs Placebo: deaths from any cause | 0 of 16 | 0 of 17 | 33 | NCT01678794 | Trial comparisons |
| Candesartan vs Placebo: serious adverse events | 0 of 16 | 0 of 17 | 33 | NCT01678794 | Trial comparisons |
| OPC-41061 7.5 mg vs OPC-41061 15 mg: serious adverse events | 0 of 10 | 1 of 10 | 20 | NCT00525265 | Trial comparisons |
| Glycyrrhetinic Acid First, Then Placebo vs Placebo First, Then Glycyrrhetinic Acid: serious adverse events | 0 of 7 | 0 of 8 | 15 | NCT00759525 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005009/comparisons